DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/563f2h/china_genetic_engi) has announced the addition of the "China Genetic Engineering Drug Industry Report, 2011-2012" report to their offering.

At present, China has at least one hundred enterprises involved in genetic engineering drugs. In recent years, the compound growth rate of genetic engineering drug market in China is as high as 49%, with an average gross margin of more than 80%.

However, the technology strength and efficacy of locally produced genetic engineering drugs are relatively weak. In particular, the pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) for injection of CSPC Pharmaceutical Group Limited that approved for marketing in March 2012 is the only homemade long-acting protein product. Still, due to the impetus of huge market capacity as well as a package of preferential policies, many domestic enterprises, including GeneScience Pharmaceuticals, Amoytop and Anhui Anke Biotechnology, are accelerating the industrialized research of long-acting protein drugs.

Although China lags behind in terms of the overall level of genetic engineering drugs, the industry is now rich R&D and industrialization experience as well as capital reserves. Thus, with a host of genetic engineering drug patents to become due, Chinese enterprises, such as Walvax, are committed to the industrialization research of monoclonal antibody, long-acting recombinant protein drugs and other generic drugs with high technical barriers.

Key Topics Covered:

1 Profile of Biopharmaceutical Industry

1.1 Definition and Classification

1.2 Genetic Engineering Drugs

2 Overview of China Genetic Engineering Drug Industry

Read more:

Research and Markets: China Genetic Engineering Drug Industry Report, 2011-2012